Regulus Therapeutics | RGLS - Assets


Regulus Therapeutics reported $93.76M in Assets for its fiscal quarter ending in September of 2024.



Assets Change Date
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Biogen USD 29.44B 232M Dec/2025
Celldex Therapeutics USD 582.98M 65.46M Dec/2025
Cipla INR 401.64B 27.77B Sep/2025
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 156.57M 58.73M Dec/2025
CSL USD 37.9B 1.5B Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Grifols EUR 23.15B 142.7M Dec/2025
Immunic USD 40.7M 20.72M Sep/2025
Incyte USD 6.96B 627.62M Dec/2025
Intrexon USD 73.16M 77.88M Jun/2024
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
Lexicon Pharmaceuticals USD 184.99M 20.94M Dec/2025
Ligand Pharmaceuticals USD 1.56B 83.86M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Omeros USD 200.57M 34.59M Jun/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 126.81B 25.48B Dec/2025
Takeda JPY 15.41T 938.47B Dec/2025